FEATURED ARTICLES
The Profit Margin Double Standard That Needs To Change
We expect pharmaceutical companies to have sizable profit margins, but we collectively scoff at research sites for achieving the same. Maria P. Ladd explores this difference in expectations and why it needs to change for the sake of the industry.
-
Why Operating Model Is The Next Competitive Frontier In Clinical Research Site Strategy – Part 1
In this three-part series, Paradigm Clinical Research CEO Kurt Mussina discusses the meaningfulness of a site's operating model to clinical trial sponsors. In part one, he first defines operating model types.
-
What Sponsors Don't See: The Systems Behind Clinical Trial Delivery
What do sponsors need from sites? Easy. How do they evaluate them? Not so easy (or accurate). In this column, Association Multisite Research Corporations (AMRC) Executive Director Jim Kremidas explains how sites and sponsors can make site evaluations better.
-
What Really Happens At The Site When Sponsors Pull Back Mid-Trial
When sponsors slow or reduce operational spending due to financial pressure, strategic pivots, or internal restructuring, sites — and patients — suffer. Curo Research CCO Amy Bland explains how sponsors can better manage operational changes.